HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1
Leukemia, Myeloid, Acute
Activating KIR genes from donors were associated with distinct outcomes of allogeneic HSCT for AML. Donor KIR2DS1 appeared to provide protection against relapse in an HLA-C-dependent manner, and donor KIR3DS1 was associated with reduced mortality. (Funded by the National Institutes of Health and others.).